NASDAQ:GRFS Grifols Q3 2026 Earnings Date & Estimates $8.18 +0.08 (+0.98%) As of 12:09 PM Eastern This is a fair market value price provided by Massive. Learn more. Grifols is estimated to report Q3 2026 earnings on Monday, November 2, 2026. The conference call is scheduled for 12:30 PM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 2, 2026Conference Call12:30 PM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Grifols in Q3 2026Grifols is expected to post earnings of $0.3202 per share on revenue of $2.21 billion. Grifols has beaten the consensus EPS estimate in 3 of its last 8 quarters.Consensus EstimatesConsensus EPS$0.3202Expected Revenue$2.21 billionRecent Track RecordLast ReportedQ4 2025Last Quarter EPS$0.3850Last Quarter Revenue$2.32 billionEPS Beat Rate3 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ4 2025 Earnings ReportQ2 2024 Earnings ReportQ2 2023 Earnings Report Grifols Q3 2026 Earnings FAQ When does Grifols report Q3 2026 earnings? Grifols (NASDAQ:GRFS) is estimated to report Q3 2026 earnings on Monday, November 2, 2026. This date is estimated from past reporting schedules and may change once the company confirms it. What time is Grifols' Q3 2026 earnings call? Grifols' Q3 2026 earnings conference call is scheduled for Monday, November 2, 2026 at 12:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Grifols? Analysts expect Grifols to post earnings of $0.3202 per share for Q3 2026. How much revenue is Grifols expected to report? The consensus revenue estimate for Grifols is $2.21 billion for Q3 2026. Grifols Earnings HeadlinesGrifols (NASDAQ:GRFS) Stock Price Target Cut by JPMorgan Chase & Co.October 28 at 1:31 AM | americanbankingnews.comPlasma Demand Supports Grifols, S.A.’s (GRFS) Path Back to Financial StrengthOctober 23, 2026 | insidermonkey.comMy next big call (under $1)17,556% on KDA. 3,900% on PRE. 2,650% on OCEAN. Every single one of these was recommended to our community before the big move happened. Now, I'm making my next big call. It's a coin under $1.00 that most investors have never heard of. But the world's largest bank is already building on it. It has a deflationary burn mechanism tied directly to institutional usage. With Bitcoin well off its highs and fear still hanging over the market, this is the exact environment where my biggest winners have been found.October 28 at 1:00 AM | Crypto 101 Media (Ad)Are options traders betting on a big move in Grifols stock?October 8, 2026 | msn.comGrifols says Canada plasma license suspension has no impactSeptember 24, 2026 | reuters.comGRFS - Grifols, S.A.September 17, 2026 | seekingalpha.comSee More Grifols Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Grifols? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Grifols and other key companies, straight to your email. Email Address About GrifolsGrifols (NASDAQ:GRFS) S.A. is a global healthcare company headquartered in Barcelona, Spain, specializing in plasma-derived medicines and diagnostic technologies. The company develops, manufactures and markets therapies made from human plasma, including immunoglobulins, albumin and coagulation factors used to treat immune deficiencies, bleeding disorders and other chronic conditions. Grifols operates a vertically integrated plasma business that includes plasma donation centers, collection and fractionation facilities, research and development, manufacturing and distribution. Its portfolio also includes diagnostic products and systems, including solutions used in blood typing, transfusion medicine and clinical laboratories. The company additionally provides hospital pharmacy products and services in selected markets. Founded in 1909, Grifols serves healthcare providers and patients in markets across North America, Europe and other international regions. Its operations include a broad network of plasma donation centers and production facilities, supporting the global supply of plasma-derived therapies. Grifols shares are listed on the Spanish stock exchanges, while its American depositary shares trade on the Nasdaq under the symbol GRFS.View Grifols ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Palantir's Q3 Bar Is Higher Than It Looks: 3 Numbers to WatchSherwin-Williams Remains Evergreen in a Frozen Housing MarketTaiwan Semiconductor Flexes Pricing Power on AI's FrontlineWelltower's Strong Earnings Couldn't Stop the Sell-Off—What's Missing?Is United Parcel Service Finally Turning the Corner?Hidden in Plain Sight: 2 Earnings Winners Investors May Have MissedApple's Foldable iPhone Sold Out in Minutes, But Wall Street Has Questions Upcoming Earnings Amazon.com (10/29/2026)Starbucks (10/29/2026)Anheuser-Busch InBev SA/NV (10/29/2026)Mondelez International (10/29/2026)Altria Group (10/29/2026)Cheniere Energy (10/29/2026)TotalEnergies (10/29/2026)Arthur J. Gallagher & Co. (10/29/2026)Lloyds Banking Group (10/29/2026)Bristol Myers Squibb (10/29/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
